Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Change in Accured Expenses for 10 years, with the latest figure at -$5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 40.35% year-over-year to -$5.0 million; the trailing twelve-month figure through Mar 2026 stood at $36.0 million (down 2.18% YoY), and the FY2025 full-year result was $37.5 million, down 14.25% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$5.0 million, down from $19.6 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $19.6 million in Q4 2025, with the low at -$10.6 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $5.3 million across 5 years, with a median of $5.3 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 456.87% — and 2023, when it jumped 345.95%.
• Kiniksa Pharmaceuticals International's Change in Accured Expenses stood at -$3.8 million in 2022, then jumped by 239.44% to $5.3 million in 2023, then jumped by 107.96% to $11.0 million in 2024, then jumped by 78.54% to $19.6 million in 2025, then sank by 125.71% to -$5.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.0 million (Q1 2026), $19.6 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.